Zacks Rating on Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD) : 5 brokerage houses believe that Amicus Therapeutics (FOLD) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Amicus Therapeutics (FOLD). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 6 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.33.

Amicus Therapeutics (FOLD) stock is expected to deviate a maximum of $3.72 from the average target price of $13.33 for the short term period. 6 Street Experts have initiated coverage on the stock with the most promising target being $19 and the most muted being $9.


Shares of Amicus Therapeutics, Inc. rose by 5.29% in the last five trading days and 22.83% for the last 4 weeks. Amicus Therapeutics, Inc. is up 3.22% in the last 3-month period. Year-to-Date the stock performance stands at -24.02%. Amicus Therapeutics (NASDAQ:FOLD): stock turned positive on Tuesday. Though the stock opened at $7.22, the bulls momentum made the stock top out at $7.555 level for the day. The stock recorded a low of $7.21 and closed the trading day at $7.37, in the green by 2.36%. The total traded volume for the day was 2,023,572. The stock had closed at $7.2 in the previous days trading.

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.